Panobinostat

Farydak (panobinostat) is a small molecule pharmaceutical. Panobinostat was first approved as Farydak on 2015-02-23. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target histone deacetylase 4, histone deacetylase 1, histone deacetylase 9, histone deacetylase 2, histone deacetylase 8, histone deacetylase 6, histone deacetylase 7, and histone deacetylase 3. Farydak's patents are valid until 2028-06-13 (FDA).